142 related articles for article (PubMed ID: 25158821)
1. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
[TBL] [Abstract][Full Text] [Related]
6. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
[TBL] [Abstract][Full Text] [Related]
7. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer.
Hitij NT; Kern I; Sadikov A; Knez L; Stanič K; Zwitter M; Cufer T
Clin Lung Cancer; 2017 May; 18(3):e187-e196. PubMed ID: 28089159
[TBL] [Abstract][Full Text] [Related]
9. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
10. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
Hasanovic A; Ang D; Moreira AL; Zakowski MF
Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
[TBL] [Abstract][Full Text] [Related]
11. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
14. Preselection of EGFR mutations in non-small-cell lung cancer patients by immunohistochemistry: comparison with DNA-sequencing, EGFR wild-type expression, gene copy number gain and clinicopathological data.
Gaber R; Watermann I; Kugler C; Vollmer E; Perner S; Reck M; Goldmann T
Rom J Morphol Embryol; 2017; 58(4):1175-1184. PubMed ID: 29556606
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
[TBL] [Abstract][Full Text] [Related]
16. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
18. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
Simonetti S; Molina MA; Queralt C; de Aguirre I; Mayo C; Bertran-Alamillo J; Sanchez JJ; Gonzalez-Larriba JL; Jimenez U; Isla D; Moran T; Viteri S; Camps C; Garcia-Campelo R; Massuti B; Benlloch S; Ramon y Cajal S; Taron M; Rosell R
J Transl Med; 2010 Dec; 8():135. PubMed ID: 21167064
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
Vora HH; Patel NA; Thakore PM; Shukla SN
Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):653-60. PubMed ID: 25789532
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical detections of EGFR status in NSCLC].
Wang J; Liu C; Zhong D; Xu D; Ning C; Ma Q
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):212-8. PubMed ID: 25936885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]